Terri Haskins, NP
Family · Geneva, NYNPI 1689632580
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,860 of the $23,978 with a category attached, or 62.0%. Braeburn Inc. accounts for 86.0% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $18,456, more than ten times the $1,675 reported in 2021. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $107.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Braeburn Inc.$21K
- Biohaven Pharmaceuticals, Inc.$828
- Pfizer$389
- Teva Pharmaceuticals USA, Inc.$299
- Johnson & Johnson$231
- Collegium Pharmaceutical, Inc.$200
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$14,86062%
- Travel & lodging$4,15717%
- Food & beverage$4,96221%
- Education$00%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Braeburn Inc. | 60 | $20,615 |
| Biohaven Pharmaceuticals, Inc. | 37 | $828 |
| Pfizer | 15 | $389 |
| Teva Pharmaceuticals USA, Inc. | 17 | $299 |
| Johnson & Johnson | 5 | $231 |
| Collegium Pharmaceutical, Inc. | 17 | $200 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $193 |
| Indivior Inc. | 7 | $139 |
| Almatica Pharma LLC | 10 | $138 |
| Alkermes, Inc. | 6 | $110 |
| Orexo US, Inc. | 4 | $74 |
| Vanda Pharmaceuticals Inc. | 2 | $70 |
| AbbVie | 3 | $66 |
| Lundbeck LLC | 2 | $62 |
| Boston Scientific | 3 | $62 |
| Biodelivery Sciences International, Inc. | 4 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Virtus Pharmaceuticals LLC | 3 | $53 |
| USWM, LLC | 2 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $50 |
| Scilex Pharmaceuticals Inc. | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 2 | $30 |
| Medtronic | 2 | $26 |
| Abbott | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
| Nevro Corp. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIXADI$19,779
- NURTEC ODT$234
- ZAVZPRET$118
How this compares
$23,978 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levorphanol Tartrate | 12 | $40,128 |
| OzempicSemaglutide | 14 | $14,393 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 42 | $7,995 |
| Buprenorphine | 25 | $7,615 |
| LinzessLinaclotide | 12 | $6,110 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $5,753 |
| Gabapentin | 143 | $4,587 |
| Hydromorphone Hcl | 44 | $4,297 |
| Fentanyl | 37 | $3,867 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 155 | $3,204 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 62 | $2,241 |
| Oxycodone Hcl | 72 | $1,715 |
| Methadone Hcl | 80 | $1,677 |
| Morphine Sulfate ErMorphine Sulfate | 58 | $1,294 |
| Celecoxib | 42 | $964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $53 | $40,12812 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Morphine Sulfate, Buprenorphine Hcl | $12 | $17,228147 claims |
| AbbVieLinzess | $66 | $6,11012 claims |
| Indivior Inc.Suboxone | $139 | $5,75314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Geneva
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.